KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $8.8 million.

  • Castle Biosciences' Gains from Investment Securities rose 253.17% to $2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.4 million, marking a year-over-year increase of 128.13%. This contributed to the annual value of $8.8 million for FY2024, which is 70.67% up from last year.
  • Per Castle Biosciences' latest filing, its Gains from Investment Securities stood at $8.8 million for FY2024, which was up 70.67% from $5.1 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Gains from Investment Securities peaked at $8.8 million during FY2024, and registered a low of -$18.3 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is -$1.5 million, with a median of $5.1 million in 2023.
  • Per our database at Business Quant, Castle Biosciences' Gains from Investment Securities surged by 2,735.29% in 2021 and then plummeted by 732.33% in 2022.
  • Over the past 5 years, Castle Biosciences' Gains from Investment Securities (Yearly) stood at $102,000 in 2020, then spiked by 2,735.29% to $2.9 million in 2021, then slumped by 732.33% to -$18.3 million in 2022, then soared by 128.07% to $5.1 million in 2023, then soared by 70.67% to $8.8 million in 2024.